Of 600 patients treated with the dopamine agonist drugs bromocriptine and lisuride for functioning pituitary tumours, eight developed drug related psychoses. Symptoms included auditory hallucinations, delusional ideas, and appreciable changes in mood. These reactions occurred with lower doses of the drugs than previously reported and remitted when treatment was stopped.
Introduction
Psychotic reactions to high doses (50-100 mg/day) of bromocriptine are well known in the treatment of parkinsonism.1 2 Recently there have been isolated reports of similar reactions associated with the lower doses (7 5-30 mg/day) used in acromegaly and hyperprolactinaemia.3 In all these cases either there was a history of psychotic illness or considerable changes in behaviour or mood, or both, had occurred before treatment. We now report the occurrence of such reactions in patients who were not so predisposed; of a series of 600 patients with hyperprolactinaemia or acromegaly treated with the dopamine agonists bromocriptine or lisuride, eight developed a clear cut psychiatric illness that appeared to be related to treatment. These reactions are of particular interest as they occurred, in four cases, with relatively low doses of dopamine agonists.
St Bartholomew's Hospital, London Our findings, however, are important as the first substantial evidence, in patients with pituitary diseases, of de novo psychotic reactions associated with dopamine agonist treatment. In all cases remission occurred after the stopping or reduction in dosage of these agents. In three patients (cases 4, 5, and 7) the relation between illness and treatment was highlighted by their further relapses when the dopamine agonist was restarted before the possible connection was noticed. Management of one patient (case 8) was affected by this earlier experience; prompt reduction in dosage twice led to early remission and minimal morbidity. As a rule the reactions were dose dependent, with a wide interpersonal variation and susceptibility in some patients at much lower doses than had previously been reported. There was no evidence that other treatment or the rate of increase in dosage were significant factors. Although several patients were regarded as being especially anxious before treatment, no consistent personality profile was noted.
The incidence of such reactions has been said to be 1-2% in parkinsonism,1' which accords roughly with our experience in pituitary diseases. A more formal survey would be required to assess this. Because, unlike patients with Parkinson's disease, our patients had no known prior disorder of dopamine metabolism, they provide clearer evidence of the role of dopamine in the pathogenesis of some psychotic illnesses. Although lisuride has an additional serotonin antagonist activity, bromocriptine does not; this reinforces our inference that it is the dopamine agonism with which these reactions are associated. The use of a specific dopamine antagonist such as pimozide while maintaining dopamine agonist treatment might have proved this point, but given the distressing condition of the patients this would clearly not have been ethical. In this respect one patient (case 3) is of particular importance as pimozide has been used successfully to treat delusional parasitosis."2 Of further interest is the form of the psychoses; the present cases combined with those reported previously have been restricted to 11 paranoid and four manic illnesses. Functional psychoses are, by tradition, broadly divided into schizophrenic and affective groups. Among patients with schizophrenia, however, a subgroup has been postulated with "positive" symptoms associated with acute illness and a good response to dopamine blocking neuroleptics.' Similar drugs are also known to be effective in mania,14 and bromocriptine has been reported to exacerbate manic symptoms.'5 Dopamine receptors may possibly take part in the pathogenesis of both paranoid and manic illnesses despite the traditional diagnostic distinction, and this common pathogenetic mechanism may be the cause of a superficial likeness in aspects of their clinical symptomatology. Although in our group all the women developed paranoid illnesses and the two men became manic, a much larger series would be required to establish any significant sex difference.
Although the reactions reported above were almost certainly due to the dopamine agonists per se, it must be noted that little is known of the incidence of psychotic symptoms in untreated acromegaly or hyperprolactinaemia. Apart from isolated case reports,"" only generalised anecdotal comment is available. In our series neither endocrine state nor the pattern of response to treatment was predictive of a psychiatric relapse. We believe, in view of the time course of relapse and remission and the relation to drug treatment, that these illnesses were not simply a reflection of the underlying endocrine disorder.
Clearly, these side effects must be recognised in view of the particular strain that may be placed on the patients and their families. Alterations in day to day behaviour, non-compliance with treatment, unusual changes in work or social life, unaccountable moodiness or misery are all suggestive and should alert the physician. The stigma of such illness remains strong, and we cannot absolutely exclude the possibility that some cases have gone unrecognised. Nevertheless, it must be emphasised that only eight out of 600 patients treated with dopamine agonists definitely developed this type of reaction.
The amount of bone lost yearly in the period immediately after the menopause approaches 2%. Although this rate then declines, bone loss will reach such a magnitude that by the age of 70 some 40% of women will have had at least one spontaneous postmenopausal fracture.' Hip fracture, the most severe, is associated with a six month mortality of 20%, and the incidence of these fractures seems to be increasing.' Since there is no treatment for osteoporosis, some means of prevention is urgently required. Oestrogen may delay or prevent postmenopausal bone loss3-5 and reduce the risk of fractures.6 This effect is probably dose related,7 and there is evidence that a combination of calcium and oestrogen may increase bone mass.3
Calcium balance is almost invariably negative in early postmenopausal women. Oestrogen probably impedes bone resorption, resulting in a decreased loss of calcium. Although it might be possible to identify potential fast bone mass losers, such women may not readily accept hormone treatment, and we cannot exclude the risk of unwanted side effects of long term administration.
The search for an agent that will increase bone mass has been intensive. Dihydroxycholecalciferol (1,25(OH)2D) stimulates calcium absorption, but its effect on bone mass, and that of its analogue lo-OHD, has proved disappointing.3 8 Heaney et al found a positive correlation between calcium intake and
